The objective of the study is to assess if charcoal prevents the absorption of budesonide and
formoterol via GI track. The assessment will be based on comparing the pharmacokinetic
parameter area under the concentration-time curve.
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Charcoal Formoterol Fumarate